Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription


2 Am J Clin Pathol
1 Am J Health Syst Pharm
1 An Bras Dermatol
1 Asia Pac J Oncol Nurs
1 Bioengineered
2 BJU Int
3 BMC Urol
1 BMJ Case Rep
1 Cancer Chemother Pharmacol
1 Cancer Rep (Hoboken)
1 Chem Biol Interact
1 Chem Res Toxicol
1 Clin Cancer Res
1 Clin Epidemiol
1 Clin Transl Oncol
2 Curr Oncol
6 Eur Urol
1 Eur Urol Focus
2 Front Cell Dev Biol
1 Front Immunol
2 Front Oncol
1 Genes (Basel)
1 Hernia
1 Int J Cancer
1 Int J Clin Pract
1 Int J Epidemiol
1 Int J Gen Med
1 Int J Mol Med
2 Int J Radiat Oncol Biol Phys
1 Int Urogynecol J
1 Iran J Med Sci
1 J Biol Regul Homeost Agents
2 J Cancer Res Clin Oncol
1 J Cancer Res Ther
1 J Cell Physiol
1 J Clin Transl Res
1 J Laparoendosc Adv Surg Tech A
1 J Minim Invasive Gynecol
1 J Patient Rep Outcomes
4 J Urol
1 Mol Genet Genomic Med
1 Mol Med Rep
1 Mol Ther Oncolytics
2 Molecules
1 Nat Methods
1 Oncogene
1 Oncology
1 Pract Radiat Oncol
2 Prog Urol
1 Sci Rep
4 Transl Androl Urol
2 Urol Oncol
1 Urologe A
2 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. XU J, Westfall DE, Lopategui JR
    "Indeterminate" UroVysion Fluorescence In Situ Hybridization Results.
    Am J Clin Pathol. 2021;156:427-432.
    PubMed         Abstract available

  2. FARAJ KS, Judge N, Chang YH, Blodgett G, et al
    Variation in Lymph Node Yield After Radical Cystectomy.
    Am J Clin Pathol. 2021;156:391-398.
    PubMed         Abstract available

    Am J Health Syst Pharm

  3. SZEWCZYK MT, Soefje SA
    Development of an innovative delivery system for bacillus Calmette-Guerin bladder administration.
    Am J Health Syst Pharm. 2021;78:60-64.
    PubMed         Abstract available

    An Bras Dermatol

  4. PARMAR NV, Al Falasi A, Almualla A
    Bacillus Calmette-Guerin vaccine-induced lupus vulgaris in a 3-year-old child.
    An Bras Dermatol. 2021;96:636-638.


  5. KANG SY, Kim KM
    Highly sensitive duplex MSI test and BAT40 germline polymorphism.
    APMIS. 2021;129:607-615.
    PubMed         Abstract available

    Asia Pac J Oncol Nurs

  6. GU Y, He H, Wang M
    Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer.
    Asia Pac J Oncol Nurs. 2021;8:586-590.
    PubMed         Abstract available


  7. JIANG L, Zuo Z, Lin J, Yang C, et al
    Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer.
    Bioengineered. 2021;12:6559-6571.
    PubMed         Abstract available

    BJU Int

  8. MORTEZAVI A, Crippa A, Edeling S, Pokupic S, et al
    Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2021;127:585-595.
    PubMed         Abstract available

  9. D'ANDREA D, Matin S, Black PC, Petros FG, et al
    Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    BJU Int. 2021;127:528-537.
    PubMed         Abstract available

    BMC Urol

  10. AICHER WK, Korn M, Reitnauer L, Maurer FB, et al
    Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma.
    BMC Urol. 2021;21:60.
    PubMed         Abstract available

  11. BUSE S, Alexandrov A, Mazzone E, Mottrie A, et al
    Surgical benchmarks, mid-term oncological outcomes, and impact of surgical team composition on simultaneous enbloc robot-assisted radical cystectomy and nephroureterectomy.
    BMC Urol. 2021;21:73.
    PubMed         Abstract available

  12. CHEN L, Lai B, Su X, Wang J, et al
    Unusual glomus tumor of the bladder: a rare case report and literature review.
    BMC Urol. 2021;21:66.
    PubMed         Abstract available

    BMJ Case Rep

  13. KRISHNA M, Kumar S, Parmar KM, Dhana Sekaran V, et al
    Unusual endophytic non-enhancing tumour in the renal pelvis: a diagnostic dilemma.
    BMJ Case Rep. 2021;14.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  14. MARCHAND M, Zhang R, Chan P, Quarmby V, et al
    Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
    Cancer Chemother Pharmacol. 2021;88:211-221.
    PubMed         Abstract available

    Cancer Rep (Hoboken)

  15. WANG L, Liu X, Yue M, Liu Z, et al
    Identification of hub genes in bladder cancer based on weighted gene co-expression network analysis from TCGA database.
    Cancer Rep (Hoboken). 2021 Sep 20:e1557. doi: 10.1002/cnr2.1557.
    PubMed         Abstract available

    Chem Biol Interact

  16. SATHIAKUMAR N, Bolaji B, Brill I, Chen L, et al
    1,3-Butadiene, styrene and selected outcomes among synthetic rubber polymer workers: Updated exposure-response analyses.
    Chem Biol Interact. 2021;347:109600.
    PubMed         Abstract available

    Chem Res Toxicol

  17. KOBAYASHI T, Toyoda T, Tajima Y, Kishimoto S, et al
    o-Anisidine Dimer, 2-Methoxy-N(4)-(2-methoxyphenyl) Benzene-1,4-diamine, in Rat Urine Associated with Urinary bladder Carcinogenesis.
    Chem Res Toxicol. 2021;34:912-919.
    PubMed         Abstract available

    Clin Cancer Res

  18. WANG H, Mei Y, Luo C, Huang Q, et al
    Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-20-4796.
    PubMed         Abstract available

    Clin Epidemiol

  19. HEKTOEN HH, Gislefoss RE, Stenehjem JS, Langseth H, et al
    Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort.
    Clin Epidemiol. 2021;13:801-811.
    PubMed         Abstract available

    Clin Transl Oncol

  20. SOTELO M, Alonso-Gordoa T, Gajate P, Gallardo E, et al
    Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
    Clin Transl Oncol. 2021;23:882-891.
    PubMed         Abstract available

    Curr Oncol

  21. KIM H, Kim O, Lee MA, Lee JY, et al
    Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells.
    Curr Oncol. 2021;28:1652-1662.
    PubMed         Abstract available

  22. SAMARA M, Papathanassiou M, Mitrakas L, Koukoulis G, et al
    DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population.
    Curr Oncol. 2021;28:1879-1885.
    PubMed         Abstract available

    Eur Urol

  23. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.

  24. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655-6.
    Eur Urol. 2021;79:657-658.

  25. PATEL SH, Kates M
    Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?
    Eur Urol. 2021;79:619-620.

  26. ANDREEV-DRAKHLIN A, Gao J, Siefker-Radtke A
    Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;79:655-656.

  27. GAKIS G
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:702.

  28. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.

    Eur Urol Focus

  29. GROBET-JEANDIN E, Pinar U, Roupret M
    Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guerin-unresponsive Non-muscle invasive Bladder Cancer: Con.
    Eur Urol Focus. 2021 Sep 17. pii: S2405-4569(21)00233.
    PubMed         Abstract available

    Front Cell Dev Biol

  30. GUO Y, Yin J, Dai Y, Guan Y, et al
    A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer.
    Front Cell Dev Biol. 2021;9:642650.
    PubMed         Abstract available

  31. HUANG M, Liu L, Zhu J, Jin T, et al
    Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer.
    Front Cell Dev Biol. 2021;9:723817.
    PubMed         Abstract available

    Front Immunol

  32. ZHOU C, Lin A, Cao M, Ding W, et al
    Activation of the DDR Pathway Leads to the Down-Regulation of the TGFbeta Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Front Immunol. 2021;12:634741.
    PubMed         Abstract available

    Front Oncol

  33. GAN K, Gao Y, Liu K, Xu B, et al
    The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.
    Front Oncol. 2021;11:653491.
    PubMed         Abstract available

  34. SUN J, Yue W, You J, Wei X, et al
    Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.
    Front Oncol. 2021;11:730716.
    PubMed         Abstract available

    Genes (Basel)

  35. CHEN TJ, Chan TC, Li WS, Li CF, et al
    Utility of EFEMP1 in the Prediction of Oncologic Outcomes of Urothelial Carcinoma.
    Genes (Basel). 2021;12.
    PubMed         Abstract available


  36. SU JS, Hoy NY, Fafaj A, Tastaldi L, et al
    The European Hernia Society classification applied to the rare cases of parastomal hernia after ileal conduit urinary diversion: a retrospective cohort of 96 patients.
    Hernia. 2021;25:125-131.
    PubMed         Abstract available

    Int J Cancer

  37. OLAH C, Hahnen C, Nagy N, Musial J, et al
    A qPCR-based method for molecular subtype classification of urinary bladder cancer - stromal gene expressions show higher prognostic values than intrinsic tumor genes.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33809.
    PubMed         Abstract available

    Int J Clin Pract

  38. LIU G, Yao Z, Chen G, Li Y, et al
    Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta-analysis.
    Int J Clin Pract. 2021;75:e14639.
    PubMed         Abstract available

    Int J Epidemiol

  39. MHATRE S, Lacey B, Sherliker P, Chatterjee N, et al
    Reproductive factors and gall-bladder cancer, and the effect of common genetic variants on these associations: a case-control study in India.
    Int J Epidemiol. 2021 Sep 22. pii: 6373963. doi: 10.1093.
    PubMed         Abstract available

    Int J Gen Med

  40. SUN J, Wei X, You J, Yue W, et al
    STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer.
    Int J Gen Med. 2021;14:5505-5516.
    PubMed         Abstract available

    Int J Mol Med

  41. QIN Z, Tong H, Li T, Cao H, et al
    SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis.
    Int J Mol Med. 2021;48.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  42. SONG YP, Mistry H, Irlam J, Valentine H, et al
    Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
    Int J Radiat Oncol Biol Phys. 2021;110:1407-1415.
    PubMed         Abstract available

  43. CHAU C, Rimmer Frcr Y, Choudhury PhD A, Leaning Frcr D, et al
    Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.
    Int J Radiat Oncol Biol Phys. 2021;110:1143-1150.
    PubMed         Abstract available

    Int Urogynecol J

  44. REY VALZACCHI GM, Pavan LI, Bourguignon GA, Cortez JP, et al
    Transvesical laparoscopy for bladder leiomyoma excision: a novel surgical technique.
    Int Urogynecol J. 2021;32:2543-2544.
    PubMed         Abstract available

    Iran J Med Sci

  45. ARIAFAR A, Habibagahi M, Jaberipour M, Khezri A, et al
    Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer.
    Iran J Med Sci. 2021;46:339-346.
    PubMed         Abstract available

    J Biol Regul Homeost Agents

  46. SHAO SP, Zhao RJ, Lu S, Wen LP, et al
    Identification of circRNA-mediated competing endogenous RNA network in the development of bladder urothelial carcinoma.
    J Biol Regul Homeost Agents. 2021;35.

    J Cancer Res Clin Oncol

  47. ALKANLI N, Ay A, Cevik G
    Investigation of the roles of IL-18 (-607 C/A) and IL-18 (-137 G/C) gene variations in bladder cancer development: case-control study.
    J Cancer Res Clin Oncol. 2021 Sep 22. pii: 10.1007/s00432-021-03808.
    PubMed         Abstract available

  48. LEE W, Nam W, Lim B, Kyung YS, et al
    Impact of preoperative chemotherapy on pathologic nodal status in muscle-invasive bladder cancer: optimal lymphadenectomy in the preoperative chemotherapy era.
    J Cancer Res Clin Oncol. 2021 Sep 23. pii: 10.1007/s00432-021-03789.
    PubMed         Abstract available

    J Cancer Res Ther

  49. Erratum: M-ds-P21 induces cell apoptosis in bladder cancer T24 cells through P53 independent pathway.
    J Cancer Res Ther. 2021;17:1140.
    PubMed         Abstract available

    J Cell Physiol

  50. SHI B, Qi J
    The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    J Cell Physiol. 2021;236:2620-2630.
    PubMed         Abstract available

    J Clin Transl Res

  51. YANG Z, Xu Y, Bi Y, Zhang N, et al
    Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
    J Clin Transl Res. 2021;7:485-500.
    PubMed         Abstract available

    J Laparoendosc Adv Surg Tech A

  52. ZHANG Y, Sun C, Tuo Z, Zhou H, et al
    Laparoscopic Cystectomy with Totally Intracorporeal Versus Extracorporeal Orthotopic Neobladder for Bladder Cancer: A Single Center Experience.
    J Laparoendosc Adv Surg Tech A. 2021 Sep 17. doi: 10.1089/lap.2021.0519.
    PubMed         Abstract available

    J Minim Invasive Gynecol

  53. DELARA R, Wasson M, Khan A
    Bladder Leiomyoma.
    J Minim Invasive Gynecol. 2021;28:1123-1124.

    J Patient Rep Outcomes

  54. RIPPING TM, Westhoff E, Aaronson NK, Van Hemelrijck M, et al
    Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer.
    J Patient Rep Outcomes. 2021;5:96.
    PubMed         Abstract available

    J Urol

  55. SHARMA V, Miest TS, Chamie K, Matin SF, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply.
    J Urol. 2021;206:1072.

  56. GHOREIFI A, Douglawi A, Djaladat H
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Letter.
    J Urol. 2021;206:1071.

  57. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who do Not Receive Guideline-Concordant Care at the Population Level.
    J Urol. 2021 Sep 22:101097JU0000000000002229. doi: 10.1097/JU.0000000000002229.
    PubMed         Abstract available

  58. CARY C, Tong Y, Linsell S, Ghani K, et al
    Ranking Important Factors for Using Postoperative Chemotherapy in Non-Muscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2021 Sep 23:101097JU0000000000002233. doi: 10.1097/JU.0000000000002233.
    PubMed         Abstract available

    Mol Genet Genomic Med

  59. HEMISSI I, Ayed H, Naimi Z, Meddeb K, et al
    Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population.
    Mol Genet Genomic Med. 2021 Sep 22:e1819. doi: 10.1002/mgg3.1819.
    PubMed         Abstract available

    Mol Med Rep

  60. ZHOU L, Wang B, Zhang Y, Yao K, et al
    Silencing circBIRC6 inhibits the proliferation, invasion, migration and epithelialmesenchymal transition of bladder cancer cells by targeting the miR4953p/XBP1 signaling axis.
    Mol Med Rep. 2021;24.
    PubMed         Abstract available

    Mol Ther Oncolytics

  61. CAO R, Ma B, Wang G, Xiong Y, et al
    Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer.
    Mol Ther Oncolytics. 2021;22:277-293.
    PubMed         Abstract available


  62. DULOVIC A, Burcul F, Culic VC, Ruscic M, et al
    Lepidium graminifolium L.: Glucosinolate Profile and Antiproliferative Potential of Volatile Isolates.
    Molecules. 2021;26.
    PubMed         Abstract available

  63. PETRELLA G, Montesano C, Lentini S, Ciufolini G, et al
    Personalized Metabolic Profile by Synergic Use of NMR and HRMS.
    Molecules. 2021;26.
    PubMed         Abstract available

    Nat Methods

  64. ZHU H, Li Q, Liao T, Yin X, et al
    Metabolomic profiling of single enlarged lysosomes.
    Nat Methods. 2021;18:788-798.
    PubMed         Abstract available


  65. CHEN X, Xu R, He D, Zhang Y, et al
    CD8(+) T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.
    Oncogene. 2021 Sep 22. pii: 10.1038/s41388-021-02019.
    PubMed         Abstract available


  66. NAIKI T, Nagai T, Sugiyama Y, Etani T, et al
    First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
    Oncology. 2021;99:622-631.
    PubMed         Abstract available

    Pract Radiat Oncol

  67. GAO RW, Tollefson MK, Thompson RH, Potretzke AM, et al
    Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.
    Pract Radiat Oncol. 2021;11:e468-e476.
    PubMed         Abstract available

    Prog Urol

  68. SAINT F, Masson-Lecomte A
    Achieving disease free distal ureteral margin at the time of radical cystectomy: Why and for whom? (an overview of literature).
    Prog Urol. 2021;31:303-315.
    PubMed         Abstract available

  69. SURLEMONT L, Nouhaud FX, Dupuis H, Delcourt C, et al
    [BCG strain shortage from 2012 to 2014: Evaluation of its impact on the management of patients with high-risk NMIBC].
    Prog Urol. 2021;31:324-331.
    PubMed         Abstract available

    Sci Rep

  70. HAM WS, Park JS, Jang WS, Choi YD, et al
    Prognostic value of prostate volume in non-muscle invasive bladder cancer.
    Sci Rep. 2021;11:18784.
    PubMed         Abstract available

    Transl Androl Urol

  71. MA T, Tian Z, Meng L, Zhang W, et al
    Young age increases the risk of lymph node positivity but improves prognosis in patients with bladder cancer treated via cystectomy: a population-based study.
    Transl Androl Urol. 2021;10:3375-3385.
    PubMed         Abstract available

  72. ZHAO J, Zhou L, Pan Y, Chen L, et al
    A systematic review and meta-analysis of radical cystectomy in the treatment of muscular invasive bladder cancer (MIBC).
    Transl Androl Urol. 2021;10:3476-3485.
    PubMed         Abstract available

  73. TAN G, Wu A, Li Z, Chen G, et al
    Bioinformatics analysis based on immune-autophagy-related lncRNAs combined with immune infiltration in bladder cancer.
    Transl Androl Urol. 2021;10:3440-3455.
    PubMed         Abstract available

  74. LI X, Huang C, Zhang X, Yang T, et al
    Discovery of bladder cancer biomarkers in paired pre- and postoperative urine samples.
    Transl Androl Urol. 2021;10:3402-3414.
    PubMed         Abstract available

    Urol Oncol

  75. SHARMA G, Sharma A, Krishna M, Devana SK, et al
    Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.
    Urol Oncol. 2021 Sep 14. pii: S1078-1439(21)00380.
    PubMed         Abstract available

  76. AWADALLA A, Harraz AM, Abol-Enein H, Laymon M, et al
    Prognostic influence of microsatellite alterations of muscle-invasive bladder cancer treated with radical cystectomy.
    Urol Oncol. 2021 Sep 16. pii: S1078-1439(21)00385.
    PubMed         Abstract available

    Urologe A

  77. SCHULZ GB, Stief CG, Saar M, Vogeli TA, et al
    [Molecular diagnostics of bladder cancer-practical ramifications].
    Urologe A. 2021 Sep 22. pii: 10.1007/s00120-021-01640.
    PubMed         Abstract available

    World J Urol

  78. COMPERAT E, Oszwald A, Wasinger G, Hansel DE, et al
    Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.
    World J Urol. 2021 Sep 23. pii: 10.1007/s00345-021-03831.
    PubMed         Abstract available

  79. CLEMENT KD, Pearce E, Gabr AH, Rai BP, et al
    Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases.
    World J Urol. 2021;39:1733-1746.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.